Table 4.
Validation measure | Mean (SD) | F1 | F2 | F3 | Perceived benefits | Perceived barriers | Decision balance | |
---|---|---|---|---|---|---|---|---|
Trust/mistrust | Barriers/costs | Support for participation | F4 Incentives | |||||
Knowledge of clinical trials | 80.19 (14.08) | 0.45** | 0.10 | 0.13 | 0.14 | 0.35** | −0.07 | 0.27** |
Consideration of future consequences | 3.63 (0.50) | 0.28** | 0.09 | 0.07 | 0.06 | 0.19* | −0.01 | 0.15 |
Emotion regulation—reappraisal | 4.26 (0.98) | 0.28** | −0.08 | 0.08 | −0.02 | 0.21* | −0.16 | 0.25** |
Emotion regulation—suppression | 2.16 (0.70) | −0.11 | 0.04 | −0.18* | −0.10 | −0.18* | 0.06 | −0.17 |
There were no significant correlations with age of AYA or developmental milestones achieved.
p < 0.05; **p < 0.01.